Targeting KRAS mutant cancers: from druggable therapy to drug resistance

Targeting KRAS mutant cancers: from druggable therapy to drug resistance

Abstract Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) is the most frequently mutated oncogene, occurring in a variety of tumor types. Targeting KRAS mutations with drugs is challenging because KRAS is considered undruggable due to the lack of classic drug binding sites. Over the past 40 years,...

Full description

Bibliographic Details
Main Authors: Chunxiao Zhu, Xiaoqing Guan, Xinuo Zhang, Xin Luan, Zhengbo Song, Xiangdong Cheng, Weidong Zhang, Jiang-Jiang Qin
Format: Article
Language:English
Published: BMC 2022-08-01
Series:Molecular Cancer
Subjects:
KRAS mutations
Druggable
Resistance
Combination therapy
Online Access:https://doi.org/10.1186/s12943-022-01629-2

Internet

https://doi.org/10.1186/s12943-022-01629-2

Similar Items